Daiichi Sankyo/Lilly's Prasugrel Clears FDA
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)
You may also be interested in...
Daiichi Sankyo To Revamp Prasugrel's U.S. Marketing After Sluggish Sales
TOKYO - An 11.1 percent upward operating income revision to ¥100 billion notwithstanding, Daiichi Sankyo is streamlining its U.S. marketing strategy for platelet inhibitor Effient (prasugrel) as the drug's July-September U.S. and European sales remained a humble ¥1.8 billion, a company spokesman said Nov. 2
Daiichi Sankyo To Revamp Prasugrel's U.S. Marketing After Sluggish Sales
TOKYO - An 11.1 percent upward operating income revision to ¥100 billion notwithstanding, Daiichi Sankyo is streamlining its U.S. marketing strategy for platelet inhibitor Effient (prasugrel) as the drug's July-September U.S. and European sales remained a humble ¥1.8 billion, a company spokesman said Nov. 2
Daiichi Sankyo's Anti-clotting Drug Effient Draws Muted Acceptance In U.S., But Cost Analysis Shows Effient Cheaper Than Plavix
TOKYO - The delayed U.S. launch of Daiichi Sankyo's and Eli Lilly's anti-blood clotting drug Effient (prasugrel) is drawing a muted initial U.S. practitioner acceptance, yet it could become more than a formidable rival of competing medicine, Plavix in the long run, company spokespersons and analysts told PharmAsia News.